What happened

NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) said NEO100 met the primary endpoint of its Phase 2a study in recurrent glioma.

Six-month progression-free survival was 48.9%. The protocol benchmark was 20%, so the result beat it by 28.9 percentage points. The one-sided p-value was 0.0047. The study covered 24 patients and had no concurrent control group.

Median overall survival, measured from the start of NEO100 at recurrence, was 26.09 months (95% CI 8.54 to 27.10). Disease control was 66.7%, and 5 patients remain on treatment. The figures come from an Aug. 8 statistical output. The database is not locked.

The company's Nov. 16 presentation also lists the Phase 1 dose-escalation study of NEO212 as complete. NEO212 is an oral temozolomide conjugate built on NEO100. The study covered 14 patients across five cohorts. Plasma levels of the NEO212 metabolites AIC and PA were low.

Why it matters

OptimistFi has argued that NeOnc creates value only if NEO100's early efficacy signal becomes a partnership or licensing deal that funds confirmatory trials. The Phase 2a results give that pitch more data, so OptimistFi's view of the filing is mixed.

The signal has limits. Under the protocol-specified RANO criteria, six-month progression-free survival was 25.8% with a p-value of 0.276. The survival figure is set against a historical salvage benchmark of roughly 6 to 9 months. The presentation calls that comparison cross-trial, not head-to-head.

The presentation also projects the global brain tumor drugs market at $5.2 billion by 2034, growing at a 9.3% compound annual rate. That is the market backdrop the company puts beside the data.

What's next

The presentation proposes a randomized Phase 3 called NEO100-301 that would test NEO100 against lomustine. The population is recurrent IDH1-mutant grade 3 or 4 astrocytoma. Overall survival is the primary endpoint. One interim analysis would support Accelerated Approval.

The first step is an End-of-Phase-2 or Type B meeting with the FDA to align on a single-trial design. Outcomes are subject to FDA review, and the presentation says there is no assurance of approval. FDA agreement on that design would strengthen the case. Disagreement would weaken it.

Sources checked automatically Nov 17, 2026 · Human review: none
Thesis impactNTHI: no published thesis yet.